Kari Grønås
Direktor/Vorstandsmitglied bei SPAGO NANOMEDICAL AB
Vermögen: 4 185 $ am 30.04.2024
Aktive Positionen von Kari Grønås
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SPAGO NANOMEDICAL AB | Direktor/Vorstandsmitglied | 01.01.2018 | - |
| Independent Dir/Board Member | 01.01.2018 | - | |
| ULTIMOVACS ASA | Direktor/Vorstandsmitglied | 01.01.2019 | - |
K & K AS
 K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Direktor/Vorstandsmitglied | 21.05.2012 | - |
| Vorstandsvorsitzender | 21.05.2012 | - | |
| Norwegian Cancer Society | Direktor/Vorstandsmitglied | - | - |
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Kari Grønås
Ehemalige bekannte Positionen von Kari Grønås
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BERGENBIO ASA | Direktor/Vorstandsmitglied | 01.02.2016 | 13.03.2019 |
| Independent Dir/Board Member | 01.02.2016 | 13.03.2019 | |
| ONCOPEPTIDES AB | Direktor/Vorstandsmitglied | - | - |
| SOFTOX SOLUTIONS | Direktor/Vorstandsmitglied | - | - |
| Norwegian Pharmaceutical Society | Vorsitzender | - | - |
| ░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Kari Grønås
| University of Oslo | Graduate Degree |
Statistik
International
| Norwegen | 11 |
| Schweden | 3 |
Operativ
| Director/Board Member | 9 |
| Independent Dir/Board Member | 2 |
| Chief Operating Officer | 1 |
Sektoral
| Health Technology | 8 |
| Commercial Services | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| BERGENBIO ASA | Health Technology |
| LYTIX BIOPHARMA | Health Technology |
| SPAGO NANOMEDICAL AB | Health Technology |
| SOFTOX SOLUTIONS | Commercial Services |
| ULTIMOVACS ASA | Health Technology |
| ONCOPEPTIDES AB | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
| Norwegian Pharmaceutical Society | |
K & K AS
K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Commercial Services |
| Norwegian Cancer Society | |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Health Technology |
- Börse
- Insiders
- Kari Grønås
- Erfahrung
